ASCO 2025 highlight

6/2 Highlights
-- ATOMIC: Atezolizumab + FOLFOX improved DFS by 50% in stage III dMMR colon cancer.
-- IMforte: Atezolizumab + lurbinectedin improved PFS (2.1 to 5.4 mo, HR 0.54) and OS (13.2 to 10.6 mo, HR 0.73) in extensive-stage SCLC maintenance.
-- DESTINY-Breast09: T-DXd + pertuzumab extended PFS by 13.8 mo vs. THP in first-line HER2-positive metastatic breast cancer (HR 0.56).

6/1 Highlights
-- HER3-DXd (Patritumab): Improved PFS vs. chemo in post-EGFR TKI setting for EGFR-mutant NSCLC (HR 0.77).
-- VERIFY (Plenary): Rusfertide reduced phlebotomy need and improved hematocrit and QoL in polycythemia vera.
-- TROPION-Lung02: Dato-DXd + pembrolizumab (with or without chemo) showed durable activity in first-line advanced NSCLC; TROP2 biomarker may guide selection.
-- KRYSTAL-7: Adagrasib + pembrolizumab showed ORR 36 to 61 percent by PD-L1 in first-line KRAS G12C-mutated NSCLC; phase 3 pending.
-- NIVOPOSTOP: Adjuvant nivolumab improved DFS (HR 0.76) after CRT in high-risk head and neck squamous cell carcinoma.
-- MATTERHORN: Durvalumab + chemotherapy improved EFS in resectable gastric and gastroesophageal junction cancer.

5/31 Highlights
-- Vepdegestrant (LBA1000): Oral PROTAC ER degrader improved PFS vs. fulvestrant in second-line or later ESR1-mutant ER-positive/HER2-negative advanced breast cancer (ORR 18.6 percent vs. 4 percent, CBR 42.1 percent vs. 20.2 percent).
-- PANOVA-3: Tumor Treatment Fields + chemotherapy improved OS (16.2 vs. 14.2 mo), D-PFS, and pain-free survival in locally advanced pancreatic cancer.
-- C-POST: Adjuvant cemiplimab improved DFS and reduced recurrence in high-risk cutaneous squamous cell carcinoma.
-- Olanzapine: Reduced radiation-related side effects in phase 3 trial.
-- CPLE (Papaya extract): Safe, low-cost option to treat chemo-induced thrombocytopenia in solid tumors.
-- Romiplostim: Evaluated for thrombocytopenia support in colorectal, gastroesophageal, and pancreatic cancers.
-- SEER-MHOS: Vaginal estrogen safe in women aged 65 and older with breast cancer; no survival harm, possible benefit (Abstract 578).